Cytospire Therapeutics Ltd shared a post on LinkedIn:
“We’re excited to share that Cytospire has completed an oversubscribed £61m ($83m) Series A financing, led by 4BIO Capital with major investors Servier Ventures, Abingworth, British Business Bank, Sound Bioventures, Criteria Bio Ventures and LifeArc Ventures.
This is a huge milestone for the company and a strong vote of confidence in Cytospire’s vision to build a new generation of cancer immunotherapies. The funding enables us to advance our lead programme, CYT X300, into the clinic and continue to build out our growing portfolio of differentiated multispecific engager antibodies.
At Cytospire, we’re developing therapies designed to precisely engage both tissue/ tumour‑resident and blood resident gamma delta T cells — with the goal of unlocking safer and more effective treatments against well‑validated cancer targets that have remained out of reach for conventional CD3‑based engager approaches.
In addition to our major investors, we are also delighted to welcome Modi Ventures, Medical Incubator Japan and Pathway Bioventures to our syndicate.
A huge thank you to our investors, partners and, most importantly, the fantastic Cytospire team. We’re just getting started — and we’re excited about what’s ahead as we move toward the clinic.
Read more about the financing.”
Servier shared a post by Cytospire Therapeutics Ltd, adding:
“Servier Ventures, our newly created corporate venture fund, is proud to announce its first investment, supporting Cytospire Therapeutics Ltd in its Series A financing.”